Response to cyclosporine therapy in patients with myelodysplastic syndrome: A clinical study of 12 cases and literature review

International Journal of Hematology

Volumn 80, Issue 1, 2004, Pages 35-42

  Ogata, Masao ^a   Ohtsuka, Eiichi ^b   Imamura, Tomoyuki ^a   Ikewaki, Junji ^a   Ogata, Yuko ^a   Kohno, Kazuhiro ^a   Nakayama, Toshiyuki ^c   Ono, Keiji ^d   Saburi, Yoshio ^b   Kikuchi, Hiroshi ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

^b OITA PREFECTURAL HOSPITAL   (Japan)

^c Kouseiren Tsurumi Hospital   (Japan)

^d Almeida Memorial Hospital   (Japan)

Author keywords

Cyclosporine; HLA DRB1*1501; MDS with erythroid hypoplasia; Myelodysplastic syndrome; Risk of malignancies

Indexed keywords

ANABOLIC AGENT; CYCLOSPORIN A; DANAZOL; FARNOQUINONE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; BONE MARROW CELL; BONE MARROW HYPOPLASIA; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LUNG CANCER; LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 19244366077     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04051     Document Type: Review

References (35)

1. Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol. 2001;114:358-361.
2. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001;25:1075-1083.
3. Selleri C, Maciejewski JP, Catalano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer. 2002;95: 1911-1922.
4. Matsutani T, Yoshioka T, Tsuruta Y, et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res. 2003;27:305-312.
5. Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996;88: 2640-2647.
6. Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63:265-278.
7. Ferrero D, Bruno B, Pregno P, et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res. 1996;20:867-876.
8. Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1997;17: 2819-2830.
9. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998; 92:68-75.
10. Raza A, Qawi H, Lisak L, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 2000;95:1580-1587.
11. Thompson JA, Gilliland DG, Prchal JT, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome: GM/EPO MDS Study Group. Blood. 2000;95:1175-1179.
12. Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ. Red cell aplasia in myelodysplastic syndrome. J Clin Pathol. 1991;44:431-432.
13. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol. 1995;91:612-617.
14. Geary CG, Marsh JC, Gordon-Smith EC. Hypoplastic myelodysplasia (MDS). Br J Haematol. 1996;94:582-583.
15. Garcia-Suarez J, Pascual T, Munoz MA, Herrero B, Pardo A. Myelodysplastic syndrome with erythroid hypoplasia/aplasia: a case report and review of the literature. Am J Hematol. 1998;58:319-325.
16. Shimamoto T, Ohyashiki K. Myelodysplastic syndrome with erythroid hypoplasia is a new clinical entity responsive to cyclosporine A therapy. Leuk Lymphoma. 2002;43:1895-1896.
17. Totterman TH, Hoglund M, Bengtsson M, Simonsson B, Almqvist D, Killander A. Treatment of pure red-cell aplasia and aplastic anaemia with ciclosporin: long-term clinical effects. Eur J Haematol. 1989;42:126-133.
18. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84: 4257-4261.
19. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997; 79:1548-1551.
20. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304-309.
21. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica. 2000;85:133-138.
22. Grigg AP, O'Flaherty E. Cyclosporin A for the treatment of pure red cell aplasia associated with myelodysplasia. Leuk Lymphoma. 2001;42:1339-1342.
23. Takata S, Kojima K, Fujii N, et al. Successful treatment with cyclosporin A of myelodysplastic syndrome with erythroid hypoplasia associated with t(6;8)(q15;q22). Cancer Genet Cytogenet. 2003;140:167-169.
24. Asano Y, Maeda M, Uchida N, et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol. 2001;80:634-638.
25. Miyata A, Yasuda Y, Fujii S, Kikuchi T. Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution [in Japanese]. Rinsho Ketsueki. 2002;43: 911-917.
26. Itoh M, Yago K, Shimada H, Tohyama K. Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome. Int J Hematol. 2002;75: 302-304.
27. Okamoto T, Okada M, Yamada S, et al. Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele. Leukemia. 2000;14:344-346.
28. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
29. Ogata M, Ono K, Ohtsuka E, et al. Spontaneous remission of Epstein-Barr virus-negative non-Hodgkin's lymphoma after withdrawal of cyclosporine in a patient with refractory anemia. Int J Hematol. 2004;79:161-164.
30. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
31. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodys-plastic syndrome. Blood. 2002;100:1570-1574.
32. Masuda M, Arai Y, Okamura T, Mizoguchi H. Pure red cell aplasia with thymoma: evidence of T-cell clonal disorder. Am J Hematol. 1997;54:324-328.
33. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res. 2003;27:783-788.
34. van den Borne BE, Landewe RB, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1930-1937.
35. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211-216.